Page last updated: 2024-11-04

tegafur and Hyperpigmentation

tegafur has been researched along with Hyperpigmentation in 5 studies

Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.

Research Excerpts

ExcerptRelevanceReference
"5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights."3.69[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996)
"Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited."2.84S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kudo, M1
Moriguchi, M1
Numata, K1
Hidaka, H1
Tanaka, H1
Ikeda, M1
Kawazoe, S1
Ohkawa, S1
Sato, Y1
Kaneko, S1
Furuse, J1
Takeuchi, M2
Fang, X1
Date, Y1
Okusaka, T1
Kim, HS1
Park, YM1
Kim, HO1
Lee, JY1
Kitajima, S1
Okamura, T1
Kobayashi, K1
Watari, N1
Inoue, H1
Enomoto, M1
Yamaguchi, S1
Rios-Buceta, L1
Buezo, GF1
PeƱas, PF1
Dauden, E1
Fernandez-Herrera, J1
Garcia-Diez, A1
Revenga, F1

Trials

1 trial available for tegafur and Hyperpigmentation

ArticleYear
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru

2017

Other Studies

4 other studies available for tegafur and Hyperpigmentation

ArticleYear
Tegafur-induced hyperpigmentation of the tongue.
    The Journal of dermatology, 2010, Volume: 37, Issue:10

    Topics: Adult; Antimetabolites, Antineoplastic; Female; Humans; Hyperpigmentation; Stomach Neoplasms; Tegafu

2010
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
    The Journal of toxicological sciences, 1996, Volume: 21 Suppl 3

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu

1996
Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
    Acta dermato-venereologica, 1997, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Erythema; Female; Foot Dermatoses; Hand Dermatoses;

1997
Cutaneous side-effects caused by Tegafur.
    International journal of dermatology, 1999, Volume: 38, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Female; Humans; Hyperpigmentation; Male; Phot

1999